148 related articles for article (PubMed ID: 32449158)
1. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?
Cappagli V; Caldarella A; Manneschi G; Piaggi P; Bottici V; Agate L; Molinaro E; Bianchi F; Elisei R
Int J Cancer; 2020 Nov; 147(10):2838-2846. PubMed ID: 32449158
[TBL] [Abstract][Full Text] [Related]
2. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
3. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
5. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
[TBL] [Abstract][Full Text] [Related]
6. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
[TBL] [Abstract][Full Text] [Related]
7. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult.
Zhao X; Chen M; Qi X; Zhu H; Yang G; Guo Y; Dong Q; Yang Q
Front Endocrinol (Lausanne); 2021; 12():805194. PubMed ID: 35154006
[TBL] [Abstract][Full Text] [Related]
8. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M
Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230
[TBL] [Abstract][Full Text] [Related]
9. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
[TBL] [Abstract][Full Text] [Related]
11. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
Gandhi S; Abhyankar A; Basu S
Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429
[TBL] [Abstract][Full Text] [Related]
12. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
14. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
Verkooijen RB; Smit JW; Romijn JA; Stokkel MP
Eur J Endocrinol; 2006 Dec; 155(6):801-6. PubMed ID: 17132748
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey.
Reiners C; Schneider R; Platonova T; Fridman M; Malzahn U; Mäder U; Vrachimis A; Bogdanova T; Krajewska J; Elisei R; Vaisman F; Mihailovic J; Costa G; Drozd V
Front Endocrinol (Lausanne); 2020; 11():381. PubMed ID: 32754115
[TBL] [Abstract][Full Text] [Related]
16. Risk of second primary cancer following differentiated thyroid cancer.
Berthe E; Henry-Amar M; Michels JJ; Rame JP; Berthet P; Babin E; Icard P; Samama G; Galateau-Sallé F; Mahoudeau J; Bardet S
Eur J Nucl Med Mol Imaging; 2004 May; 31(5):685-91. PubMed ID: 14747959
[TBL] [Abstract][Full Text] [Related]
17. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
Mei X; Yao X; Feng F; Cheng W; Wang H
BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
[TBL] [Abstract][Full Text] [Related]
18. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
19. Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients.
Drozd V; Schneider R; Platonova T; Panasiuk G; Leonova T; Oculevich N; Shimanskaja I; Vershenya I; Dedovich T; Mitjukova T; Grelle I; Biko J; Reiners C
Front Endocrinol (Lausanne); 2020; 11():567385. PubMed ID: 33193085
[No Abstract] [Full Text] [Related]
20. Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer.
Szczepanek-Parulska E; Wojewoda-Korbelak M; Borowczyk M; Kaluzna M; Brominska B; Ziemnicka K; Czepczynski R; Baczyk M; Ruchala M
Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):115-123. PubMed ID: 30221905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
